Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q2

4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥24.2bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥24.7bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥1.7bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥3.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥1.9bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.3bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥1.9bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥3.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥2.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥38.7bnat 2022-09-30Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥39.1bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.3bnat 2022-09-30Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥10.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥12.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥11.6bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥4.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥249m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥503m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥937m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥2.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.52022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.162022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥204.382021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥122.92021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥107.182022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥203.772021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.1%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥213m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥16.2bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥320m
—segment totalrevenue2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥24.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥4m
—segment totalsegment profit2022-04-01 → 2022-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥177m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.6bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.8bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥8.1bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥523m
—segment totalrevenue2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥24.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥8m
—segment totalsegment profit2021-04-01 → 2021-09-30¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 519
ItemContextValueUnit
Current portion of long term loans payablePrior1YearInstant715000000JPY
Current portion of long term loans payableCurrentQuarterInstant2672000000JPY
Income taxes payablePrior1YearInstant1725000000JPY
Income taxes payableCurrentQuarterInstant748000000JPY
Provision for bonusesPrior1YearInstant610000000JPY
Provision for bonusesCurrentQuarterInstant590000000JPY
Other clPrior1YearInstant2652000000JPY
Other clCurrentQuarterInstant2313000000JPY
Current liabilitiesPrior1YearInstant11389000000JPY
Current liabilitiesCurrentQuarterInstant11505000000JPY
Long term loans payablePrior1YearInstant2340000000JPY
Long term loans payableCurrentQuarterInstant－JPY
Net defined benefit liabilityPrior1YearInstant1919000000JPY
Net defined benefit liabilityCurrentQuarterInstant1881000000JPY
Asset retirement obligations nclPrior1YearInstant133000000JPY
Asset retirement obligations nclCurrentQuarterInstant134000000JPY
Other nclPrior1YearInstant995000000JPY
Other nclCurrentQuarterInstant868000000JPY
Noncurrent liabilitiesPrior1YearInstant5389000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2885000000JPY
LiabilitiesPrior1YearInstant16778000000JPY
LiabilitiesCurrentQuarterInstant14390000000JPY
Capital stockPrior1YearInstant3371000000JPY
Capital stockCurrentQuarterInstant3371000000JPY
Capital surplusPrior1YearInstant3387000000JPY
Capital surplusCurrentQuarterInstant3387000000JPY
Retained earningsPrior1YearInstant17479000000JPY
Retained earningsCurrentQuarterInstant18226000000JPY
Treasury stockPrior1YearInstant-1343000000JPY
Treasury stockCurrentQuarterInstant-1296000000JPY
Shareholders equityPrior1YearInstant22895000000JPY
Shareholders equityCurrentQuarterInstant23688000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant500000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant518000000JPY
Valuation and translation adjustmentsPrior1YearInstant500000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant518000000JPY
Subscription rights to sharesPrior1YearInstant82000000JPY
Subscription rights to sharesCurrentQuarterInstant82000000JPY
Net assetsPrior1YearInstant23478000000JPY
Net assetsCurrentQuarterInstant24290000000JPY
Liabilities and net assetsPrior1YearInstant40256000000JPY
Liabilities and net assetsCurrentQuarterInstant38680000000JPY
Net salesPrior1YTDDuration24693000000JPY
Net salesCurrentYTDDuration24151000000JPY
Cost of salesPrior1YTDDuration15873000000JPY
Cost of salesCurrentYTDDuration16490000000JPY
Gross profitPrior1YTDDuration8820000000JPY
Gross profitCurrentYTDDuration7661000000JPY
Selling general and administrative expensesPrior1YTDDuration5683000000JPY
Selling general and administrative expensesCurrentYTDDuration5920000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass